|
1
|
Saeedi P, Petersohn I, Salpea P, Malanda
B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA,
Ogurtsova K, et al: IDF Diabetes Atlas Committee: Global and
regional diabetes prevalence estimates for 2019 and projections for
2030 and 2045: Results from the International Diabetes Federation
Diabetes Atlas, 9th edition. Diabetes Res Clin Pract.
157(107843)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Turner RC, Millns H, Neil HA, Stratton IM,
Manley SE, Matthews DR and Holman RR: Risk factors for coronary
artery disease in non-insulin dependent diabetes mellitus: United
Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 316:823–828.
1998.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zafrir B and Plutzky J: Atherogenesis,
coronary heart disease and insulin resistance syndrome in diabetes.
In: International Textbook of diabetes mellitus. DeFronzo RA,
Ferrannini E, Zimmet P and Alberti KGMM (eds). John Wiley &
Sons, Ltd., West Sussex, pp1031-1045, 2015.
|
|
4
|
Bratu O, Mischianu D and Constantinoiu S:
Transobturator urethral suspension surgical treatment of urinary
incontinence in men. Chirurgia (Bucur). 108:250–255.
2013.PubMed/NCBI
|
|
5
|
Hsia DS and Cefalu WT: The relationship
between obesity and type 2 diabetes - the role of gut factors. In:
International Textbook of Diabetes Mellitus. DeFronzo RA,
Ferrannini E, Zimmet P and Alberti KGMM (eds). John Wiley &
Sons, Ltd., West Sussex, pp469-478, 2015.
|
|
6
|
World Health Organization: Obesity and
overweight. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight.
Accessed March 31, 2020.
|
|
7
|
Younossi ZM, Tampi RP, Racila A, Qiu Y,
Burns L, Younossi I and Nader F: Economic and clinical burden of
nonalcoholic steatohepatitis in patients with type 2 diabetes in
the U.S. Diabetes Care. 43:283–289. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vernon G, Baranova A and Younossi ZM:
Systematic review: The epidemiology and natural history of
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
in adults. Aliment Pharmacol Ther. 34:274–285. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Marchesini G and Mazzotti A: NAFLD
incidence and remission: Only a matter of weight gain and weight
loss? J Hepatol. 62:15–17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Estes C, Razavi H, Loomba R, Younossi Z
and Sanyal AJ: Modeling the epidemic of nonalcoholic fatty liver
disease demonstrates an exponential increase in burden of disease.
Hepatology. 67:123–133. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Marchesini G, Day CP, Dufour JF, Canbay A,
Nobili V, Ratziu V, Tilg H, Roden M, Gatsaldelli A, Yki-Jarvinen H,
et al: European Association for the Study of Obesity (EASO):
EASL-EASD-EASO Clinical practice guidelines for the management of
non-alcoholic fatty liver disease. Obes Facts. 9:65–90.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Radaelli MG, Martucci F, Perra S,
Accornero S, Castoldi G, Lattuada G, Manzoni G and Perseghin G:
NAFLD/NASH in patients with type 2 diabetes and related treatment
options. J Endocrinol Invest. 41:509–521. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tang A, Hallouch O, Chernyak V, Kamaya A
and Sirlin CB: Epidemiology of hepatocellular carcinoma: Target
population for surveillance and diagnosis. Abdom Radiol (NY).
43:13–25. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gastaldelli A and Cusi K: From NASH to
diabetes and from diabetes to NASH: Mechanisms and treatment
options. JHEP Rep. 1:312–328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Milić S, Lulić D and Štimac D:
Non-alcoholic fatty liver disease and obesity: Biochemical,
metabolic and clinical presentations. World J Gastroenterol.
20:9330–9337. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schuppan D, Surabattula R and Wang XY:
Determinants of fibrosis progression and regression in NASH. J
Hepatol. 68:238–250. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Singh S, Allen AM, Wang Z, Prokop LJ,
Murad MH and Loomba R: Fibrosis progression in nonalcoholic fatty
liver vs nonalcoholic steatohepatitis: A systematic review and
meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol.
13:643–54.e1, 9, quiz e39-e40. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chalasani N, Younossi Z, Lavine JE, Diehl
AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and
management of non-alcoholic fatty liver disease: Practice Guideline
by the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American
Gastroenterological Association. Hepatology. 55:2005–2023.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Loomba R, Abraham M, Unalp A, Wilson L,
Lavine J, Doo E and Bass NM: Nonalcoholic Steatohepatitis Clinical
Research Network. Association between diabetes, family history of
diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.
Hepatology. 56:943–951. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ciupińska-Kajor M, Hartleb M, Kajor M,
Kukla M, Wyleżoł M, Lange D and Liszka L: Hepatic angiogenesis and
fibrosis are common features in morbidly obese patients. Hepatol
Int. 7:233–240. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hazlehurst JM, Woods C, Marjot T, Cobbold
JF and Tomlinson JW: Non-alcoholic fatty liver disease and
diabetes. Metabolism. 65:1096–1108. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bril F and Cusi K: Management of
nonalcoholic fatty liver disease in patients with type 2 diabetes:
A call to action. Diabetes Care. 40:419–430. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hernaez R, Lazo M, Bonekamp S, Kamel I,
Brancati FL, Guallar E and Clark JM: Diagnostic accuracy and
reliability of ultrasonography for the detection of fatty liver: A
meta-analysis. Hepatology. 54:1082–1090. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Castera L, Friedrich-Rust M and Loomba R:
Noninvasive assessment of liver disease in patients with
nonalcoholic fatty liver disease. Gastroenterology.
156:1264–1281.e4. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yki-Järvinen H: Diagnosis of non-alcoholic
fatty liver disease (NAFLD). Diabetologia. 59:1104–1111.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Promrat K, Kleiner DE, Niemeier HM,
Jackvony E, Kearns M, Wands JR, Fava JL and Wing RR: Randomized
controlled trial testing the effects of weight loss on nonalcoholic
steatohepatitis. Hepatology. 51:121–129. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Vilar-Gomez E, Martinez-Perez Y,
Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B,
Gonzalez-Fabian L, Friedman SL, Diago M and Romero-Gomez M: Weight
loss through lifestyle modification significantly reduces features
of nonalcoholic steatohepatitis. Gastroenterology. 149:367–78.e5;
quiz e14-e15. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mummadi RR, Kasturi KS, Chennareddygari S
and Sood GK: Effect of bariatric surgery on nonalcoholic fatty
liver disease: Systematic review and meta-analysis. Clin
Gastroenterol Hepatol. 6:1396–1402. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Della Pepa G, Vetrani C, Lombardi G,
Bozzetto L, Annuzzi G and Rivellese AA: Isocaloric dietary changes
and non-alcoholic fatty liver disease in high cardiometabolic risk
individuals. Nutrients. 9(1065)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ryan MC, Itsiopoulos C, Thodis T, Ward G,
Trost N, Hofferberth S, O'Dea K, Desmond PV, Johnson NA and Wilson
AM: The Mediterranean diet improves hepatic steatosis and insulin
sensitivity in individuals with non-alcoholic fatty liver disease.
J Hepatol. 59:138–143. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Eslamparast T, Tandon P and Raman M:
Dietary composition independent of weight loss in the management of
non-alcoholic fatty liver disease. Nutrients. 9(800)2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Epingeac ME, Gaman MA, Diaconu C, Gad M
and Gaman AM: The evaluation of oxidative stress in obesity. Rev
Chim. 70:2241–2244. 2019.
|
|
33
|
Athyros VG, Polyzos SA, Kountouras J,
Katsiki N, Anagnostis P, Doumas M and Mantzoros CS: Non-alcoholic
fatty liver disease treatment in patients with type 2 diabetes
mellitus; New kids on the block. Curr Vasc Pharmacol. 18:172–181.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cusi K, Orsak B, Bril F, Lomonaco R, Hecht
J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, et al:
Long-term pioglitazone treatment for patients with nonalcoholic
steatohepatitis and prediabetes or type 2 diabetes mellitus: A
randomized trial. Ann Intern Med. 165:305–315. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Sanyal AJ, Chalasani N, Kowdley KV,
McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE,
Tonascia J, Unalp A, et al: NASH CRN: Pioglitazone, vitamin E, or
placebo for nonalcoholic steatohepatitis. N Engl J Med.
362:1675–1685. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ranjbar G, Mikhailidis DP and Sahebkar A:
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and
steatohepatitis: Think out of the box! Metabolism.
101(154001)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Armstrong MJ, Gaunt P, Aithal GP, Barton
D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA,
et al: LEAN trial team: Liraglutide safety and efficacy in patients
with non-alcoholic steatohepatitis (LEAN): A multicentre,
double-blind, randomised, placebo-controlled phase 2 study. Lancet.
387:679–690. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yilmaz Y, Yonal O, Deyneli O, Celikel CA,
Kalayci C and Duman DG: Effects of sitagliptin in diabetic patients
with nonalcoholic steatohepatitis. Acta Gastroenterol Belg.
75:240–244. 2012.PubMed/NCBI
|
|
39
|
Asakawa M, Mitsui H, Akihisa M, Sekine T,
Niitsu Y, Kobayashi A, Miyake A, Hashimoto N, Kawamura M and Ogawa
Y: Efficacy and safety of sitagliptin for the treatment of diabetes
mellitus complicated by chronic liver injury. Springerplus.
4(346)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kuchay MS, Krishan S, Mishra SK, Farooqui
KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, et
al: Effect of empagliflozin on liver fat in patients with type 2
diabetes and nonalcoholic fatty liver disease: A randomized
controlled trial (E-LIFT Trial). Diabetes Care. 41:1801–1808.
2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Diaconu C: Treatment of diabetes in
patients with heart failure. In: Proceedings of the 3rd
International Conference on Interdisciplinary Management of
Diabetes Mellitus and its Complications - Diabetes Mellitus as
Cardiovascular Disease. INTERDIAB 2017, Bucharest, pp170-177,
2017.
|
|
42
|
Targher G, Bertolini L, Rodella S, Zoppini
G, Lippi G, Day C and Muggeo M: Non-alcoholic fatty liver disease
is independently associated with an increased prevalence of chronic
kidney disease and proliferative/laser-treated retinopathy in type
2 diabetic patients. Diabetologia. 51:444–450. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Musso G, Gambino R, Tabibian JH, Ekstedt
M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK,
Charatcharoenwitthaya P, et al: Association of non-alcoholic fatty
liver disease with chronic kidney disease: A systematic review and
meta-analysis. PLoS Med. 11(e1001680)2014.PubMed/NCBI View Article : Google Scholar
|
